T1	intervention 68 95	carboplatin plus paclitaxel
T2	control 110 136	epirubicin plus paclitaxel
T3	total-participants 483 485	91
T4	intervention-participants 529 531	47
T5	control-participants 545 547	44
T6	outcome 623 646	objective response rate
T7	iv-bin-percent 681 686	89.4%
T8	cv-bin-percent 691 696	79.5%
T9	outcome 714 722	pCR rate
T10	iv-bin-percent 763 768	38.6%
T11	cv-bin-percent 773 778	14.0%
T13	outcome 835 845	5-year RFS
T14	iv-bin-percent 851 856	77.6%
T15	cv-bin-percent 861 866	56.2%
T16	outcome 944 946	OS
T17	outcome 1039 1055	thrombocytopenia
T18	eligibility 1083 1114	Patients with stage II/III TNBC
T19	outcome-Measure 1376 1410	pathologic complete response (pCR)
T12	outcome 1672 1688	pCR rate and RFS
T20	outcome-Measure 1445 1472	relapse-free survival (RFS)
T21	outcome-Measure 1474 1495	overall survival (OS)
T22	outcome-Measure 1500 1506	safety
